ATAPAC Study (TauroLock Activity in Adult Cancer Patients)

Inclusion Criteria: * Patients older than 18 years * Performance Index (WHO score) ≤ 2 * Patient with a solid cancer receiving an IV anti-tumor treatment * Presence of a totally implantable CVC * Anti-tumoral therapy administered by a totally implantable CVC * Metastatic and / or (neo) adjuvant treatment * Full hospitalised and / or day-hospital patients * Informed written consent * Social Health security insurance Exclusion Criteria: * Hematological cancer patients * HIV-positive patients and/ or patients receiving an active immunosuppressive therapy * Patients presenting a febrile episode within 4 days prior to randomisation * Patients with neutropenia grade ≥ 2 (ANC ≤ 1000/mm3) on a blood testing older than 7 days * Patients on IV antibiotic therapy * Patients on total and / or peripheral parental nutrition * Patients with a previous CLABSI history * Allergy to citrate or taurolidine * Patients who are not able to give an informed consent * Patients under guardianship * Patients under judicial protection * Pregnant or breastfeeding woman